Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bone formation in senile osteoporosisbone formation in senile osteoporosis

ABSTRACT: Bone formation in senile osteoporosisbone formation in senile osteoporosis

PROVIDER: PRJNA865868 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR20339871.fastq.gz	Fastqsanger.gz
	SRR20339872.fastq.gz	Fastqsanger.gz
	SRR20339873.fastq.gz	Fastqsanger.gz
	SRR20339874.fastq.gz	Fastqsanger.gz
	SRR20339875.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 21

Similar Datasets

BMAL1-TTK-H2Bub1 loop deficiency contributes to impaired BM-MSC-mediated bone formation in senile osteoporosis

Project description:BMAL1-TTK-H2Bub1 loop deficiency contributes to impaired BM-MSC-mediated bone formation in senile osteoporosis

| PRJNA865870 | ENA

Bone formation in senile osteoporosisbone formation in senile osteoporosis

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-08-03 | GSE210426 | GEO

Transcriptome Alteration Between Young and Senile Human Bone MSC

Project description:In order to uncover mechanisms of hBMSC senescence, we performed high-throughput RNA-seq using young and senile human bone MSC (hBMSC).

2023-09-20 | GSE160273 | GEO

Transcriptome Alteration Between Young and Senile Human Bone MSC

Project description:Transcriptome Alteration Between Young and Senile Human Bone MSC

| PRJNA672852 | ENA

The long noncoding RNA lnc-ob1 facilitates bone formation by upregulating Osterix in osteoblasts

Project description:Long noncoding RNAs (lncRNAs) have emerged as integral regulators of physiology and disease, but specific roles of lncRNAs in bone disease remain largely unknown. Here, we show that lnc-ob1 regulates osteoblast activity and bone formation in mice by upregulating the osteogenic transcription factor Osterix. Expression of lnc-ob1 is enriched in osteoblasts and upregulated during osteoblastogenesis. We demonstrate that osteoblast-specific knock-in of lnc-ob1 enhances bone formation and increases bone mass. Pharmacological overexpression of lnc-ob1 specifically in osteoblasts confers resistance to ovariectomy-induced osteoporosis in mice. In humans, expression of the homologue, lnc-OB1, decreases with age in osteoblasts of patients with osteoporosis. Mechanistically, lnc-ob1 upregulates the expression of Osterix in mouse and human osteoblasts, probably via inhibition of H3K27me3 methylation. Our data indicate that lnc-OB1 regulates bone formation and might be a drug target for the treatment of osteoporosis.

2019-03-28 | GSE112318 | GEO

Metridium senile

Project description:Metridium senile overview

| PRJNA256218 | ENA

REGγ is essential to maintain bone homeostasis by degrading TRAF6, preventing osteoporosis

Project description:Primary osteoporosis, manifesting as decreased bone mass and increased bone fragility, is a “silent disease” that is often ignored until a bone breaks. Accordingly, it is urgent to develop reliable biomarkers and novel therapeutic strategies for osteoporosis treatment. Here, we identified REGγ as a potential biomarker of osteoporotic populations through proteomics analysis. Next, we demonstrated that REGγ deficiency increased osteoclast activity and triggered bone mass loss in REGγ knockout (KO) and bone marrow-derive macrophage (BMM)-conditional REGγ KO mice. However, the osteoclast activity decreased in BMM-conditional REGγ overexpression mice. Mechanistically, we defined that REGγ-20S proteasome directly degraded TRAF6 to inhibit bone absorption in a ubiquitin-independent pathway. More importantly, BMM-conditional Traf6 KO with REGγ KO mice could “rescue” the osteoporosis phenotypes. Based on NIP30 (a REGγ “inhibitor”) dephosphorylation by CKII inhibition activated the ubiquitin-independent degradation of TRAF6, we selected TTP22, an inhibitor of CKII, and defined that TTP22 could alleviate osteoporosis in vitro and in vivo. Overall, our study reveals a unique function of NIP30/REGγ/TRAF6 axis in osteoporosis and provides a potential therapeutic drug TTP22 for osteoporosis.

2024-10-27 | PXD057237 |

Mogrol attenuates osteoclast formation and bone resorption by inhibiting the TRAF6/MAPK/NF-κB signaling pathway in vitro and protects against osteoporosis in postmenopausal mice

Project description:Osteoporosis is a serious public health problem that results in fragility fractures, especially in postmenopausal women. Because the current therapeutic strategy for osteoporosis has various side effects, a safer and more effective treatment is worth exploring. It is important to examine natural plant extracts during new drug design due to low toxicity. Mogrol is an aglycon of mogroside, which is the active component of Siraitia grosvenorii and exhibits anti-inflammatory, anticancer and neuroprotective effects. Here, we demonstrated that mogrol dose-dependently inhibited osteoclast formation and function. To confirm the mechanism, RNA sequencing (RNA-seq), real-time PCR (RT–PCR), immunofluorescence and Western blotting were performed. The RNA-seq data revealed that mogrol had an effect on genes involved in osteoclastogenesis. Furthermore, RT–PCR indicated that mogrol suppressed osteoclastogenesis-related gene expression, including CTSK, ACP5, MMP9 and DC-STAMP, in RANKL-induced bone marrow macrophages (BMMs). Western blotting demonstrated that mogrol suppressed osteoclast formation by blocking TNF receptor-associated factor 6 (TRAF6)-dependent activation of the mitogen-activated protein kinase (MAPK)/nuclear factor-B (NF-κB) signaling pathway, which decreased two vital downstream transcription factors, the nuclear factor of activated T cells calcineurin-dependent 1 (NFATc1) and c-Fos proteins expression. Furthermore, mogrol dramatically reduced bone mass loss in postmenopausal mice. In conclusion, these data showed that mogrol may be a promising procedure for osteoporosis prevention or therapy.

2022-02-18 | GSE196742 | GEO

Metridium senile

Project description:Metridium senile Genome sequencing

| PRJNA212399 | ENA

Novel Role for Alpha-2-Macroglobulin (A2M) as a Disease Modifying Protein in Senile Osteoporosis

Project description:Novel Role for Alpha-2-Macroglobulin (A2M) as a Disease Modifying Protein in Senile Osteoporosis

| PRJNA1018558 | ENA